UK surge in cell and gene therapy trials
A surge in cell and gene therapy trials – an increase of 37% since 2017 – highlights the UK’s leading position as a developmental hub in the sector, says the Cell and Gene Therapy Catapult.
Read More
Tag: Industrial Strategy Challenge Fund
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
- Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
